A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS).

Trial Profile

A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Metoprolol/tesofensine (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Sponsors Saniona
  • Most Recent Events

    • 03 Apr 2017 Status changed to recruiting, according to a Saniona media release.
    • 20 Mar 2017 According to a Saniona media release, based on company's meeting with the European Medicines Agency (EMA) for scientific advice and now collaborates with an international consortium to advance clinical trials for Prader-Willi syndrome, it has decided to include additional clinical endpoints and a questionnaire, was developed and validated for assessing changes in hyperphagic behavior in PWS patients, a critical issue in their daily lives.
    • 20 Mar 2017 According to a Saniona media release, the regulatory agencies in Czech Republic and Hungary have approved company's clinical trial applications and the trial is expected to be initiated in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top